COVID-19 And The Drug Pricing Debate: Disruption Helps Industry More Than R&D

15 Oct 2020

• By Michael McCaughan

CEO accountability hearing in US House shows that the COVID-19 outbreak is helping to blunt attacks on the drug industry over its pricing – just not entirely in the way the industry hoped.

US Capitol building, Washington DC (f11photo/Shutterstock.com) — • Source: Shutterstock

COVID-19 And The Drug Pricing Debate: Disruption Helps Industry More Than R&D

More from Pricing Debate

More from Market Access